N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246
Online ISSN 1827-160X
MONOCLONAL ANTIBODIES FOR IN VIVO APPLICATIONS - PART II
Riva P. 1, Franceschi G. 1, Frattarelli M. 2, Riva N. 3, Guiducci G. 2, Cremonini A. M. 2, Giuliani G. 1, Casi M. 4
1 Dept of Nuclear Medicine and Istituto Oncologico Romagnolo;
2 Neurosurgery Department “M. Bufalini” Hospital Cesena;
3 Department “Pierantoni” Hospital Forlì, Italy;
4 Medical Oncology
Background. The loco-regional radioimmunotherapy may control malignant gliomas and, in particular glioblastomas whose prognosis is very dismal.
Methods. 152 patients (91 in 131I and 61 in 90Y studies) received loco-regional-radioimmunotherapy (RIT). They had: 2 oligodendroglioma, 7 anaplastic oligodendroglioma, 18 anaplastic astrocytoma and 124 glioblastoma. 79 were newly diagnosed tumours, 93 had recurrent lesions. Two 131I or 90Y labelled antitenascin monoclonal antibodies BC-2 and BC-4, were utilised. The patients had radioimmunotherapy following customary regimens. The radioactive Mabs were infused into the surgical crater.
Results. The accretion of the radiopharmaceutical in the neoplastic area was remarkable. The mean radiation dose to the tumour per administration was 300 Gy in 131I group and 600 Gy in 90Y subset. In 131I glioblastoma cases we registered: 10 stable diseases (SD), 9 partial responses (PR), 23 no evidences of disease (NED) and 1 complete response (CR). In 90Y glioblastoma class we documented 14 PD, 4 SD, 6 PR and 9 NED. In 131I glioblastoma subset, the median survival was 19 months (17 months in cases with bulky lesions and 25 months in patients with minimal disease). In 90Y group the median survival of glioblastoma was 18 months (16 in cases with bulky lesions and 31 in patients with small or minimal disease). The patients with oligodendroglioma, anaplastic oligodendroglioma and anaplastic astrocytoma, obtained better responses.
Conclusions. The loco-regional RIT was well tolerated and proved its effectiveness, mainly in cases with reduced tumour burden after the customary regimens.